

Merck and Siemens accelerate AI and data-driven drug discovery and development

24 September 2025 | News

MoU signed to deliver end-to-end digital workflows from drug discovery to manufacturing



Merck and Siemens have signed a new Memorandum of Understanding (MoU), extending their strategic partnership to accelerate digital transformation in the life science industry by connecting digital and physical products.

The agreement focuses on delivering integrated software solutions, systems and consumables that harness automation, data and AI to connect drug discovery, development, and manufacturing. This agreement marks the first joint use of technology acquired by Siemens as part of the acquisition of Dotmatics that was completed in July 2025.

The collaboration will focus on digital-first solutions that close workflow gaps in drug discovery and biomanufacturing by integrating Merck's software-as-a-service (SaaS) products with Siemens' digital ecosystem. Initial pilot projects include making Merck's AI tools and digital applications available in Luma, Siemens' Scientific Intelligence Platform acquired as part of Dotmatics. This will give scientists a single environment that links product ordering with immediate access to the digital tools and insights they need to make faster, data-driven decisions.

Building on these projects, Siemens and Merck will pursue additional joint projects and explore deeper integration over time. These initiatives include co-developing smarter data management tools and intuitive interfaces that make advanced processes easier for scientists to use. The partnership is also evaluating digital marketplaces that would give customers streamlined access to complementary technologies and services.

Image caption- Jean-Charles Wirth (L), Member of the Executive Board and CEO Life Science, Merck and Cedrik Neike (R), Member of the Managing Board at Siemens AG and CEO of Siemens Digital Industries